Maud Kamal
Overview
Explore the profile of Maud Kamal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
2550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Balogh G, Jorge N, Dupain C, Kamal M, Servant N, Le Tourneau C, et al.
J Integr Bioinform
. 2024 Dec;
21(4).
PMID: 39654143
Many publicly available databases provide disease related data, that makes it possible to link genomic data to medical and meta-data. The cancer genome atlas (TCGA), for example, compiles tens of...
2.
Michel M, Heidary M, Mechri A, Da Silva K, Gorse M, Dixon V, et al.
Clin Cancer Res
. 2024 Dec;
PMID: 39620930
Purpose: The detection of circulating tumor DNA, which allows non-invasive tumor molecular profiling and disease follow-up, promises optimal and individualized management of patients with cancer. However, detecting small fractions of...
3.
Marret G, Lamy C, Vacher S, Cabel L, Sene M, Ahmanache L, et al.
Oral Oncol
. 2024 Nov;
160:107111.
PMID: 39612700
Objectives: Head and neck squamous cell carcinoma (HNSCC) is characterized by significant genetic intra-tumor heterogeneity (ITH), which may hinder precision medicine strategies that depend on results from single tumor-biopsy specimens....
4.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, et al.
Nat Commun
. 2024 Oct;
15(1):9370.
PMID: 39478018
No abstract available.
5.
Lebedeva A, Belova E, Kavun A, Taraskina A, Bartoletti M, Bieche I, et al.
Mol Diagn Ther
. 2024 Oct;
29(1):91-101.
PMID: 39368036
Background: The widespread use of next-generation sequencing in clinical practice has contributed to the accumulation of a large number of genomic findings associated with targeted therapy; therefore, the problem of...
6.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, et al.
Nat Commun
. 2024 Oct;
15(1):8603.
PMID: 39366934
Metastatic urothelial carcinoma (mUC) is a lethal cancer, with limited therapeutic options. Large-scale studies in early settings provided critical insights into the genomic and transcriptomic characteristics of non-metastatic UC. The...
7.
Ramachandran D, Mao Q, Liao D, Kamal M, Schurmann P, Eisenblatter R, et al.
Mol Carcinog
. 2024 Oct;
64(1):14-24.
PMID: 39352309
The reverse transcriptase subunit of telomerase, TERT, is frequently activated in high-grade dysplasia and invasive cancers of the uterine cervix. Telomerase activation through hypomethylation of the TERT promoter holds promise...
8.
Sablin M, Gestraud P, Jonas S, Lamy C, Lacroix-Triki M, Bachelot T, et al.
Br J Cancer
. 2024 Aug;
131(6):1060-1067.
PMID: 39090361
Background: Copy number alterations (CNA) are acquired during the evolution of cancers from their early stage to metastatic stage. This study aims at analysing the clinical value of the identified...
9.
El Beaino Z, Dupain C, Marret G, Paoletti X, Fuhrmann L, Martinat C, et al.
J Pathol
. 2024 Jul;
264(2):186-196.
PMID: 39072750
Tumor immunological characterization includes evaluation of tumor-infiltrating lymphocytes (TILs) and programmed cell death protein ligand-1 (PD-L1) expression. This study investigated TIL distribution, its prognostic value, and PD-L1 expression in metastatic...
10.
Jacquin N, Flippot R, Masliah-Planchon J, Grisay G, Brillet R, Dupain C, et al.
NPJ Precis Oncol
. 2024 Jul;
8(1):147.
PMID: 39025947
Metastatic carcinoma of presumed renal origin (rCUP) has recently emerged as a new entity within the heterogeneous entity of Cancers of Unknown Primary (CUP) but their biological features and optimal...